[Comment] Future of once-weekly insulins in type 2 diabetes: efficacy and safety

Type 2 diabetes is characterised by insulin resistance and progressive β-cell decline. Around a third of the people with type 2 diabetes require insulin by 8 years after diagnosis.1 Despite the availability of non-insulin glucose-lowering drugs, there has been no decline, and even a mild increase, in the prevalence of insulin use in real-world studies.2,3 Fear of hypoglycaemia and the frequency of insulin injections negatively affect patient acceptance and adherence to optimal insulin use, especially in older adults.